OTLK — Outlook Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649989 ·
Last close
$0.40
Market Cap
$48.37M
52W High
$0.51
52W Low
$0.16
ADV30
16,456,750
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,439 | -21,888 | -14,026,987 | -4,453,081 | 21,892,406 | 7,748,226 | 50,887,177 |
| Dec 2025 | -1,207,833 | -1,237,459 | -13,483,952 | -23,058,135 | 18,238,574 | 8,677,424 | 56,788,039 |
| Sep 2025 | -91,787 | -1,008,302 | -17,314,606 | -13,292,769 | 18,584,183 | 8,083,085 | 50,771,844 |
| Jun 2025 | 1,505,322 | 1,065,507 | -15,748,680 | -20,152,502 | 22,391,540 | 8,900,814 | 59,581,265 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-55,801,213
Investing CF
—
Financing CF
$58,776,061
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-628,767,898
Inventory
$3,458,064
Receivables
$114,609
ST Investments
—
EBIT TTM
$-60,561,873
Pretax Income TTM
$-104,412,441
Interest Exp TTM
$313,507
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$333,141
EBITDA
$-60,454,584
Free Cash Flow
$-25,471,416
Enterprise Value
$56,895,256
Total Cash
$7,748,226
Total Debt
$27,187,960
Shares Out
120,863,252
Trailing EPS
$-1.13
Book Value
$-0.60
ROE
—
ROA
-184.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 1,413,535 | -67,061,666 | -62,424,863 | 18,584,183 | 50,771,844 | — | -51,829,437 |
| Sep 2024 | 0 | -71,703,235 | -75,366,714 | 28,823,154 | 101,899,664 | — | -68,793,858 |
| Sep 2023 | 0 | -53,126,382 | -58,982,668 | 32,300,601 | 46,738,378 | — | -42,973,398 |
| Sep 2022 | 0 | -63,070,753 | -66,052,264 | 28,527,751 | 19,791,180 | — | -56,674,559 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BKHA | Black Hawk Acquisition Corp | $49.22M | $11.85 | — |
| ATYR | aTYR PHARMA INC | $47.49M | $0.48 | — |
| ESLA | Estrella Immunopharma, Inc. | $49.49M | $1.15 | — |
| ELUT | ELUTIA INC. | $50.40M | $1.14 | — |
| MGX | Metagenomi Therapeutics, Inc. | $51.20M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally?
2026-05-26 13:08 · Yahoo
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
2026-05-26 11:00 · Yahoo
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
2026-05-15 21:25 · Yahoo
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-15 20:05 · Yahoo
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
2026-04-23 20:05 · Yahoo
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-04-22 12:30 · Yahoo
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
2026-04-21 13:05 · Yahoo
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
2026-04-07 12:50 · Yahoo
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
2026-03-25 20:05 · Yahoo
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
2026-03-24 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.